최종훈 (중앙대학교) | 한빛사논문 > 한빛사

한빛사논문

조회508

중앙대학교

CV File 114 kb

J. Control. Release, Volume 342, February 2022, Pages 321-336 | https://doi.org/10.1016/j.jconrel.2022.01.004 Surface glycan targeting for cancer nano-immunotherapy

Yonghyun Choi^a, Jiwon Kim^a, Jayoung Chae^a, Joohye Hong^a, Jongjun Park^a, Eunseo Jeong^a, Hayoung Kim^a, Masayoshi Tanaka^b, Mina Okochi^b, Jonghoon Choi^a,*

^aSchool of Integrative Engineering, Chung-Ang University, Seoul, Republic of Korea
^bDepartment of Chemical Science and Engineering, Tokyo Institute of Technology, 2-12-1-S1-24, O-okayama, Meguro-ku, Tokyo 152-8552, Japan

^*Corresponding author.

Abstract

Cancer immunotherapy is an emerging therapeutic strategy for cancer treatment. Most of the immunotherapeutics approved by the FDA regulate the innate immune system and associated immune cell activity, with immune check inhibitors in particular having transformed the field of cancer immunotherapy due to their significant clinical potential. However, previously reported immunotherapeutics have exhibited undesirable side effects, including autoimmune toxicity and inflammation. Controlling these deleterious responses and designing therapeutics that can precisely target specific regions are thus crucial to improving the efficacy of cancer immunotherapies. Recent studies have reported that cancer cells employ glycan−immune checkpoint interactions to modulate immune cell activity. Thus, the recognition of cancer glycan moieties such as sialoglycans may improve the anticancer activity of immune cells. In this review, we discuss recent advances in cancer immunotherapies involving glycans and glycan-targeting technologies based on nanomaterial-assisted local delivery systems.

Keywords : Glycosylation, Cancer glycan, Cancer immunotherapy, Glycan targeting, Nanoparticle

논문정보

형식Review Paper
게재일2022년 02월 (BRIC 등록일 2022-02-17)
연구진국내(교신)+국외 연구진
분야 바이오·의료융합 > 바이오센싱 및 나노바이오물질

댓글 작성 로그인

CV 열람하기

연락처 보기